Coloplast A/S Explores New Horizons with Peristeen Light Clinical Study

Coloplast A/S ((GB:0QBO)) announced an update on their ongoing clinical study.

Study Overview: Coloplast A/S is launching an exploratory clinical investigation titled ‘An Explorative Clinical Investigation to Understand the Clinical Benefits of Peristeen Light.’ The study aims to assess the clinical benefits of the Peristeen Light device in adults experiencing faecal incontinence, chronic constipation, or requiring extensive bowel management. The primary goal is to evaluate changes in bowel function over a 12-week period using this device.

Intervention/Treatment: The intervention being tested is the Peristeen Light, a transanal irrigation system. This device is designed to assist patients in managing bowel function more effectively, potentially improving their quality of life by reducing symptoms associated with faecal incontinence and constipation.

Study Design: The study is interventional with a single-group model, meaning all participants will receive the Peristeen Light treatment. There is no masking involved, and the primary purpose is treatment-focused, aiming to directly observe the effects of the device on participants.

Study Timeline: The study is not yet recruiting, with an initial submission date of June 27, 2025, and the latest update submitted on August 27, 2025. These dates are crucial as they indicate the study’s progression and readiness to commence participant enrollment.

Market Implications: This clinical update could positively influence Coloplast A/S’s stock performance by demonstrating innovation and commitment to addressing unmet medical needs. Successful outcomes may enhance investor confidence and position Coloplast favorably against competitors in the medical device industry, particularly in the bowel management segment.

The study is ongoing, with further details available on the ClinicalTrials portal.